Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aleglitazar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 20/20 | 1.00 |
| ▸ | PPARA known ✓ | Q07869 | 20/20 | 1.00 |
| ▸ | PPARD | Q03181 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aleglitazar SCHEMBL482285 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| Aleglitazar SCHEMBL30193480 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| Aleglitazar SCHEMBL483251 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| Aleglitazar SCHEMBL19457970 | 0.94 | PPARG (0.89) | PPARGPPARAPPARD | |
| Aleglitazar SCHEMBL1739488 | 0.94 | PPARG (0.89) | PPARGPPARAPPARD | |
| SCHEMBL5762070 | 0.93 | PPARG (0.88) | PPARGPPARAPPARD | |
| SCHEMBL5756987 | 0.93 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL5756999 | 0.93 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL5759624 | 0.92 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL5759618 | 0.92 | PPARG (1.00) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137661-A1 | PPAR-ALPHA/GAMMA AGONIST FOR USE IN THE TREATMENT OF LIVER FAILURE | GENFIT (FR) | 2026-05-21 | — | — | US | claimed |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4725479-A1 | PPAR AGONISTS FOR TREATMENT OF DISEASES ASSOCIATED WITH AATD | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-04-15 | — | — | EP | claimed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250367216-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250367217-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| EP-4615433-A1 | PPAR-ALPHA/GAMMA AGONIST FOR USE IN THE TREATMENT OF LIVER FAILURE | Genfit (FR) | 2025-09-17 | — | — | EP | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| US-20250082781-A1 | METHODS OF LOWERING BLOOD GLUCOSE AND TREATING TYPE 2 DIABETES BY ACTIVATION OF PDE4D3 | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2025-03-13 | — | — | US | claimed |
| US-7262303-B2 | Process for the production of chiral propionic acid derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | claimed |
| JP-2007506800-A | — | — | 2007-03-22 | — | — | JP | claimed |
| EP-1670792-A1 | PROCESS FOR THE PREPARATION OF CHIRAL PROPIONIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-21 | — | — | EP | claimed |
| EP-1392295-B1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | EP | claimed |
| WO-2005030764-A1 | PROCESS FOR THE PREPARATION OF CHIRAL PROPIONIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-04-07 | — | — | WO | claimed |
| US-20050070714-A1 | Process for the production of chiral propionic acid derivatives | HOFFMANN-LA ROCHE INC. | 2005-03-31 | — | — | US | claimed |
| EP-1392295-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2004-03-03 | — | — | EP | claimed |
| US-6642389-B2 | For therapy of diabetes | HOFFMANN-LA ROCHE INC. | 2003-11-04 | — | — | US | claimed |
| US-20030055265-A1 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2003-03-20 | — | — | US | claimed |
| WO-2002092084-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137661-A1 | PPAR-ALPHA/GAMMA AGONIST FOR USE IN THE TREATMENT OF LIVER FAILURE | PPARA, PPARD, PPARG | PPARG 3/4885PPARA 1/4885PPARD 2/4885 |
| US-20250082781-A1 | METHODS OF LOWERING BLOOD GLUCOSE AND TREATING TYPE 2 DIABETES BY ACTIVATION OF PDE4D3 | PDE4D, PDE4A, PDE4B | PPARG 129/4885PPARA 210/4885PPARD 312/4885 |
| US-20250367216-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | PPARD, NR1H4, PPARG | PPARG 3/4885PPARA 4/4885PPARD 1/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 467/4885PPARA 1336/4885PPARD 1359/4885 |
| US-20050070714-A1 | Process for the production of chiral propionic acid derivatives | HRH4, HRH3, HRH1 | PPARG 805/4885PPARA 499/4885PPARD 460/4885 |
| US-20250367217-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | PPARD, NR1H4, PPARG | PPARG 3/4885PPARA 4/4885PPARD 1/4885 |
| US-20030055265-A1 | Oxazole derivatives | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.